IL-1 Blockade Reduces Inflammation in Pulmonary Arterial Hypertension and Right Ventricular Failure: A Single-Arm, Open-Label, Phase IB/II Pilot Study

Am J Respir Crit Care Med. 2019 Feb 1;199(3):381-384. doi: 10.1164/rccm.201809-1631LE.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Heart Failure / complications*
  • Humans
  • Hypertension, Pulmonary / complications*
  • Inflammation / complications*
  • Inflammation / prevention & control*
  • Interleukin 1 Receptor Antagonist Protein / administration & dosage
  • Interleukin-1 / antagonists & inhibitors*
  • Male
  • Middle Aged
  • Pilot Projects
  • Pulmonary Artery
  • Ventricular Dysfunction, Right / complications*
  • Ventricular Function, Right

Substances

  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1